BAFF Antibody [4.62] | 36-119

BAFF Antibody [4.62] | 36-119 | Gentaur UK, US & Europe Distribution

Host: Rat

Reactivity: Human

Homology: N/A

Immunogen: HA-tagged human BAFF.

Research Area: Immunology, Innate Immunity, Functional Assays

Tested Application: E, Func, IP

Application: ELISA: (as a detection antibody) . Functional Application: Inhibition of human BAFF binding. Immunoprecipitation: (1:200) .

Specificiy: Recognizes human BAFF.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95% (SDS-PAGE)

Clonality: Monoclonal

Clone: 4.62

Isotype: IgG2a

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: BLyS; TALL-1; CD257; B Cell Activating Factor; TNFSF13B

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: BAFF is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE) . Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL) .